Clinical Trial: Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088211) titled 'Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC' on July 20.

Brief Summary: This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of Sacituzumab Tirumotecan and Toripalimab in the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients with trop2 and CPS positive. The participants would receive Sacituzumab Tirumotecan and Toripalimab until termination criteria are met.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventi...